MARKET COMPOSITE
Pharmaceuticals: Generic Stocks19-00-2024 20:00:00 PM
Price
$119.93
-0.78%
The list of companies include ABEO-Abeona Therapeutics Inc, BBIO-BridgeBio Pharma Inc, COCP-Cocrystal Pharma Inc, CPHI-China Pharma Holdings Inc., JAGX-Jaguar Health Inc, LFVN-Lifevantage Corporation, TARO-Taro Pharmaceutical Industries, TXMD-TherapeuticsMD Inc, ZTS-Zoetis Inc, SMTI-Sanara MedTech Inc
* Latest intraday update before market close @ 19:45:20 PM 04/19/2024
Summary
:
Average return is down -0.3%
Median return is up 0.3%
5 out of 8 stocks are up (limited to those with intraday pricing feeds).
Top Movers
:
ZTS -4.3%SMTI -3.8%BBIO -1.0%TARO + 0.2%RDY + 0.4%

Aggregated price index with volume information

Summary:

  • Pharmaceuticals: Generic stocks down 0.8% on average while median return down 0.3% in a day
  • Pharmaceuticals: Generic stocks down 1.4% on average while median return down 1.3% in a week
  • Pharmaceuticals: Generic stocks down 6.8% on average while median return down 7.4% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks
Ticker
1d
7d
30d
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
LFVN0.6%
8.2%
-3.7%
29.380.872.910.464%87.9M5%52%57/\-560.0%
TEVA0.6%
-3.3%
-4.6%
-25.790.711.120.6912%14.4B53%37-\-/At resistance2200.2%
RDY0.3%
-0.4%
-2.3%
-14.060.070.06-28%11.9B11%37/-/Below support860.1%
TARO0.1%
0.5%
-0.2%
-1.531.635.091.6B2%13%54\/\-/2200.2%
SMTI-0.6%
0.8%
-10.3%
13.36288M2%7%45\/\/At support1280.1%
BBIO-0.8%
-7.8%
-13.6%
-6.260.1915.651051.044.4B13%95%30-/Below support4395.6%
TXMD-2.1%
-6.5%
-20.9%
-1.89-0.226.5121.5M16%46%23/\-At support1050.0%
ZTS-4.3%
-2.3%
-14.3%
28.92.9621.5312.5532%67B1%94%25/\-/Below support2200.1%
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
Detail Performance Summary
  • 1M winners are : Winners for past month are
  • 1M losers are : Losers for past month are $SMTI -10.3%, $BBIO -13.6%, $ZTS -14.3%, $TXMD -20.9%
  • 1W winners are : Winners for past week are $LFVN 8.2%, $SMTI 0.8%, $TARO 0.5%
  • 1W losers are : Losers for past week are $ZTS -2.3%, $TEVA -3.3%, $TXMD -6.5%, $BBIO -7.8%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 10.4%, for the past 3 months is 4.9%

In the past month for a 5 days rolling window, the highest corrrelation is 29.8%, the lowest correlation is -8.5%, the latest correlation is 2.3%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 56.8% between BBIO and TEVA

The lowest correlation is -33.5% between LFVN and TARO

Stock news

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

    Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. The US stock market started 2024 optimistically. In the first quarter, the fund returned 8.29% (gross) and 8.09% (net) compared to 11.41% for the Russell 1000 Growth Index and […]

    SALT LAKE CITY, April 18, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2024, after the stock market closes on Thursday, May 2, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors inte

    Zoetis Inc's Dividend Analysis04-17-2024 11:02:42 AM

    Zoetis Inc (NYSE:ZTS) recently announced a dividend of $0.43 per share, payable on 2024-06-04, with the ex-dividend date set for 2024-04-18. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Zoetis Inc's dividend performance and assess its sustainability.

    In the latest trading session, Zoetis (ZTS) closed at $149.77, marking a -0.14% move from the previous day.

    Company News for Apr 15, 202404-15-2024 13:28:00 PM

    Companies In The Article Are:INTC,ZTS,X,NPSCY and PGR

    Zoetis stock crumbled Friday after a report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats.

    An article in The Wall Street Journal highlights scrutiny of the company’s arthritis treatments for pets.

    Zoetis Inc (NYSE:ZTS) tumbled to a 52-week low after a media report suggested the company’s arthritis shots, Librela and Solensia, could have sickened dogs and cats. Solensia (frunevetmab) gained FDA approval in January 2022 for pain associated with osteoarthritis in cats. It became the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. In May 2023, the FDA approved Librela (bedinvetmab) for pain associated with osteoarthritis in dogs. Librela is t

    Shares of Zoetis fell Friday after the Journal reported that the company's arthritis drugs for dogs and cats have come under scrutiny over possible side effects. Shares of Zoetis were recently down more than 7%, on pace for their lowest close in more than a year. According to The Journal, health regulators in the U.S. and Europe have received thousands of reports of side effects and are conducting reviews of the drugs, sold as Librela for dogs and Solensia for cats.